Sign in
CompletedNo phase

THC Crossover Study

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
14 people enrolled
Started
30 Oct 2020
Ended
25 Jun 2024
Type of study
Interventional, 3 groups
Treatments tested
  • Smoked Cannabis
  • Vaped Cannabis
  • Tobacco Cigarette
Record updated
1 July 2024

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Healthy on the basis of medical history and limited physical examination, as described below:; Heart rate < 105 beats per minute (BPM); Systolic Blood Pressure < 160 and > 90*; Diastolic Blood Pressure < 100 and > 50*; *Considered out of range if both machine and manual readings are above/below these thresholds
  • Current regular user of cannabis who smokes cannabis as joint or blunt at least 3 times a week for past 3 months
  • History of cannabis vaporizer use or willingness to use the vaporizer in the study
  • Current tobacco cigarette use who smokes ≥ 5 cigarettes per day
  • Saliva cotinine ≥ 50 ng/ml
  • Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use

Who cannot take part

  • Concurrent regular use of smokeless tobacco or pipes [occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study]
  • Medications:; Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs).; Concurrent use of nicotine-containing medications; Psychiatric medications: current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate
  • Drug/Alcohol Dependence:; Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program; Positive toxicology test at the screening visit (THC \& prescribed medications okay); Methadone replacement therapy
  • Concurrent participation in another clinical trial
  • Unstable medical conditions:; Heart disease; Uncontrolled hypertension; Thyroid disease (okay if controlled with medication); Diabetes; Hepatitis B or C or Liver disease; Glaucoma; Prostatic hypertrophy
  • Psychiatric conditions:; Current or past schizophrenia, and/or current or past bipolar disorder; Adult onset attention deficit hyperactivity disorder (ADHD); Participants with current or past depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion; History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
  • Other/Misc. Chronic Health Conditions:; Oral thrush; Fainting; Untreated thyroid disease; Other "life threatening illnesses" as per study physician's discretion
  • History of marijuana-induced psychosis or paranoia after smoking marijuana
  • Pregnancy:; Pregnancy (self-reported and urine pregnancy test); Breastfeeding (determined by self-report)
  • Inability to communicate in English
  • Scoring a 2 or higher on the Severity of Dependence Scale for cannabis use
  • Planning to quit smoking or vaping within the next 60 days

Where in United States

  • University of California San FranciscoSan Francisco, United States
  • Zuckerberg San Francisco General HospitalSan Francisco, United States

About the trial

What the trial wants to find out

This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.

The 3 groups in the trial

  • Smoked Cannabis, Vaped Cannabis, or Tobacco CigaretteOther group

    * Abstinence from any product night before hospital admission * Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette * 6-hr abstinence and blood draws (PK) * 2 hr Free use session w/ video monitoring * Free use of assigned product * 12-hr cardiovascular (CV) monitoring * Circadian blood draws * 12-hr urine collection

    Treatment: Smoked Cannabis, Vaped Cannabis, and Tobacco Cigarette

  • Either of the 2 remaining productsOther group

    * Abstinence from any product night before hospital admission * Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette * 6-hr abstinence and blood draws (PK) * 2 hr Free use session w/ video monitoring * Free use of assigned product * 12-hr CV monitoring * Circadian blood draws * 12-hr urine collection

    Treatment: Smoked Cannabis, Vaped Cannabis, and Tobacco Cigarette

  • Remaining productOther group

    * Abstinence from any product night before hospital admission * Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette * 6-hr abstinence and blood draws (PK) * 2 hr Free use session w/ video monitoring * Free use of assigned product * 12-hr CV monitoring * Circadian blood draws * 12-hr urine collection

    Treatment: Smoked Cannabis, Vaped Cannabis, and Tobacco Cigarette

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cardiovascular Effects of Cannabis Compared to Tobacco Use
Record updated
1 July 2024